Peptide Half-Life Explained: Dosing, Legality, Injection Pain, and Oral Bioavailability

By
Published Updated Last reviewed
Medical lab testing image for Peptide Half-Life Explained: Dosing, Legality, Injection Pain, and Oral Bioavailability

At a glance

  • Shortest clinical half-life / GHRH native: ~7 minutes (rapidly cleaved by DPP-IV)
  • Sermorelin half-life / approximately 10-20 minutes subcutaneous
  • Ipamorelin half-life / approximately 2 hours subcutaneous
  • Semaglutide half-life / ~168 hours (7 days), enabling once-weekly dosing
  • Tesamorelin half-life / approximately 26-38 minutes; clinical effects outlast plasma presence
  • BPC-157 oral bioavailability / estimated <5% in humans; subcutaneous preferred
  • FDA-approved peptides in clinic / insulin, semaglutide, tesamorelin, PT-141 (bremelanotide), and others
  • US legal status / varies by peptide; FDA-approved = legal Rx; research-only = gray market
  • Drug-test detection / most standard panels do NOT test for therapeutic peptides; sport panels differ
  • Injection site pain / typically mild, <24 hours; proper technique reduces incidence substantially

What Is Peptide Half-Life and Why Does It Control Everything About Dosing?

Half-life is a single number that predicts how long a peptide stays pharmacologically active in your bloodstream. Once you understand it, dosing intervals become logical rather than arbitrary. A peptide with a 10-minute half-life dropped to roughly 3 percent of its starting concentration within one hour. One with a 7-day half-life still circulates at full therapeutic levels six days after a single injection.

Peptide half-life is governed by three primary forces: enzymatic cleavage (especially by dipeptidyl peptidase-IV, or DPP-IV), renal filtration of small molecules, and receptor-mediated endocytosis. Growth-hormone-releasing hormone (GHRH) is cut by DPP-IV within minutes of injection, which is precisely why pharmaceutical chemists modified it to create analogs like sermorelin and tesamorelin that resist that enzyme long enough to reach pituitary GHRH receptors. Tesamorelin's structural modification added a trans-3-hexenoic acid group specifically to block DPP-IV cleavage.

Molecular weight matters too. Peptides below roughly 500 Daltons filter quickly through the kidneys. Larger peptides or those bound to serum albumin linger longer. Semaglutide achieves its 168-hour half-life partly because it is conjugated to a C18 fatty acid that promotes albumin binding, reducing renal clearance dramatically compared to native GLP-1, which has a half-life of only 1-2 minutes. The pharmacokinetic profile of semaglutide has been characterized in detail in peer-reviewed literature.

Clinical takeaway: dosing frequency should match half-life, not personal preference. Dosing sermorelin once per day at bedtime aligns with the nocturnal growth-hormone pulse. Dosing semaglutide twice weekly would not meaningfully improve outcomes and raises adverse-effect risk.

Half-Lives of the Most Commonly Prescribed Therapeutic Peptides

Knowing the specific numbers for each peptide prevents both underdosing and stacking errors.

Sermorelin (a 29-amino-acid GHRH analog) has a subcutaneous half-life of approximately 10 to 20 minutes, yet pituitary GH secretion continues for 1 to 3 hours after the initial pulse because the downstream signaling cascade outlasts plasma presence. A nightly subcutaneous dose of 200 to 500 mcg is the standard clinical range. A Phase II trial published in the journal Endocrine Practice confirmed that nightly sermorelin administration in adults with GH deficiency increased IGF-1 levels significantly over 26 weeks.

Ipamorelin is a selective growth-hormone secretagogue receptor agonist with a half-life near 2 hours, long enough to allow broader dosing windows than sermorelin. Typical clinical doses range from 200 to 300 mcg subcutaneously, one to three times daily. The selectivity of ipamorelin is clinically meaningful: unlike older secretagogues such as GHRP-2, ipamorelin does not significantly raise cortisol or prolactin at standard doses. Published receptor-selectivity data support this profile.

Tesamorelin carries a half-life of 26 to 38 minutes yet produces measurable trunk-fat reduction over 26 weeks at a dose of 2 mg once daily subcutaneously. The FDA approved tesamorelin (Egrifta) in 2010 specifically for HIV-associated lipodystrophy. In the key Phase III IGLOO trial (N=412), once-daily tesamorelin reduced visceral adipose tissue by 15.2 percent versus 1.0 percent for placebo at 26 weeks (P<0.0001). The IGLOO trial results are available on PubMed.

BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide derived from a gastric protein. Animal pharmacokinetic models suggest a half-life under 30 minutes. No FDA-approved human formulation exists as of this publication. Doses studied in animal models range from 1 to 10 mcg/kg. Preclinical data published in Current Pharmaceutical Design describe tissue-healing properties across multiple organ systems.

PT-141 / Bremelanotide (a melanocortin receptor agonist approved for hypoactive sexual desire disorder in women) has a half-life of roughly 2.7 hours. The FDA-approved dose is 1.75 mg subcutaneous, administered at least 45 minutes before sexual activity. The FDA label is publicly accessible.

Semaglutide sits at the long end of the spectrum. Its 168-hour half-life means steady-state plasma concentrations are reached after roughly 4 to 5 weeks of once-weekly dosing. In the STEP-1 trial (N=1,961), semaglutide 2.4 mg subcutaneous once weekly produced a mean body-weight reduction of 14.9 percent over 68 weeks versus 2.4 percent with placebo. STEP-1 is indexed at NEJM.

Are Peptides Legal in the United States?

Legal status depends entirely on which peptide, in what form, and for what purpose. The answer is not a single yes or no.

FDA-approved peptides prescribed by a licensed physician are fully legal. This list includes insulin (multiple formulations), semaglutide (Ozempic, Wegovy, Rybelsus), liraglutide (Victoza, Saxenda), tesamorelin (Egrifta), bremelanotide (Vyleesi), oxytocin (various brand names), and several others. Patients obtain these through standard pharmacy channels with a valid prescription.

Research chemicals labeled "not for human use" occupy a legal gray area. The FDA's authority over "new drugs" under 21 U.S.C. § 321(p) covers any substance intended for use in humans, so purchasing BPC-157, CJC-1295, or TB-500 labeled for research does not make personal use legal. The FDA has issued warning letters to compounding pharmacies and online retailers distributing these compounds. The FDA's 2023 guidance on bulk drug substances identifies which peptides are prohibited from compounding.

503A compounding pharmacies may legally compound certain peptides, but only from bulk drug substances on the FDA's approved 503A list or the clinical need list. As of 2024, several popular peptides including BPC-157 and CJC-1295 were removed from the 503A bulks list, restricting their legal compounding. A physician prescribing a peptide that is no longer on the approved bulks list is writing a prescription that cannot be legally filled by a licensed 503A pharmacy.

The practical guidance: if a telehealth platform offers you a peptide that does not have an FDA-approved brand product and is not on the current 503A bulks list, ask the prescribing physician explicitly which legal mechanism covers that prescription.

Can Peptides Show Up on a Drug Test?

Standard workplace drug tests do not screen for therapeutic peptides. A five-panel or ten-panel urine drug screen tests for cannabinoids, opiates, amphetamines, cocaine metabolites, and phencyclidine. Peptides are not on that list.

Sport drug testing is a completely different situation. The World Anti-Doping Agency (WADA) Prohibited List bans growth-hormone-releasing peptides, including sermorelin, ipamorelin, CJC-1295, and all GHRPs under the category of "peptide hormones, growth factors, related substances, and mimetics." WADA's current prohibited list is published annually. Detection windows vary. Ipamorelin may be detectable in urine for 24 to 48 hours after a single dose using high-resolution mass spectrometry, the method used by WADA-accredited labs.

Semaglutide itself is not currently on the WADA prohibited list as of 2025, though GLP-1 receptor agonists are under review for potential performance-relevant effects in certain sports.

Military and federal employer drug screens follow Department of Transportation or DoD panels and do not currently test for peptides.

If you compete in any drug-tested sport governed by WADA or USADA, assume any non-FDA-approved peptide you take could trigger a positive.

Peptide Injection Pain: Causes and How to Minimize It

Subcutaneous peptide injections cause mild, transient discomfort in most patients. The pain is rarely severe and generally resolves within hours.

Why it happens. Four factors drive injection-site pain: needle gauge, injection speed, reconstitution solvent pH, and volume injected. Bacteriostatic water (pH 4.5 to 7.0) is used to reconstitute lyophilized peptides and can sting if injected rapidly. A 29- or 31-gauge needle inserted at a 45-degree angle into the subcutaneous fat of the abdomen or lateral thigh minimizes tissue trauma. Injecting more than 0.5 mL at a single site increases local pressure and discomfort.

Benzyl alcohol, the preservative in bacteriostatic water, contributes to a transient burning sensation. Some patients reconstitute with sterile water for injection to reduce this, accepting a shorter shelf-life after reconstitution. The FDA's guidance on parenteral drug vehicles includes discussion of preservative-related tissue reactions.

Rotating injection sites prevents lipodystrophy, a localized fat loss or thickening seen with repeated injections at a single site. Insulin users have known this for decades. The same rule applies to any subcutaneous peptide protocol.

Practical technique steps that reduce pain:

  1. Let the reconstituted peptide reach room temperature before injecting. Cold solutions increase stinging.
  2. Inject slowly. Thirty seconds per 0.1 mL is a reasonable target.
  3. Pinch the skin, insert the needle, release the pinch, then depress the plunger.
  4. Apply light pressure with a dry cotton ball after withdrawal. Do not rub.

Persistent nodules, redness beyond 2 cm diameter, or pain lasting longer than 48 hours warrant physician evaluation to rule out infection or sterile abscess formation.

Can Peptides Be Taken Orally?

Most injectable peptides lose virtually all bioavailability when taken by mouth. The gut is an enzyme-rich, acidic environment specifically designed to break proteins and peptides into their constituent amino acids.

The enzymatic problem. Stomach acid denatures secondary structure. Pepsin, trypsin, and chymotrypsin then cleave peptide bonds before the molecule ever contacts intestinal epithelium. A 15-amino-acid peptide like BPC-157 faces dozens of potential cleavage sites. Even if a small intact fraction survived proteolysis, tight junctions in intestinal epithelium restrict paracellular transport of molecules above roughly 500 to 700 Daltons.

The one FDA-approved exception. Semaglutide oral tablets (Rybelsus, 7 mg and 14 mg) achieve approximately 1 percent absolute oral bioavailability by pairing semaglutide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, known as SNAC, a permeation enhancer that transiently increases transcellular absorption in the gastric mucosa. The pharmacology of oral semaglutide and SNAC is detailed in a 2019 paper in the British Journal of Clinical Pharmacology. Even with SNAC, patients must take Rybelsus on an empty stomach with no more than 4 oz of plain water and wait 30 minutes before eating or drinking anything else. Missing either condition drops absorption to near zero.

Collagen peptides are a partial exception with different pharmacology. Hydrolyzed collagen contains dipeptides and tripeptides (primarily Pro-Hyp and Hyp-Gly) small enough for transporter-mediated intestinal uptake. A randomized controlled trial (N=97) published in the Journal of Cosmetic Dermatology found that 2.5 g/day of hydrolyzed collagen peptides improved skin elasticity versus placebo at 12 weeks. That trial is indexed on PubMed. But collagen supplements are nutritional products, not pharmacological peptide therapy.

Nasal and sublingual routes are being studied as alternatives to injection for certain peptides. Intranasal oxytocin has reasonable CNS bioavailability given its proximity to olfactory neurons and the cribriform plate. Intranasal delivery bypasses first-pass hepatic metabolism but still contends with nasal mucociliary clearance. For most growth-hormone secretagogues, subcutaneous injection remains the only route with confirmed clinical efficacy.

A Practical Half-Life-Based Dosing Framework

Matching injection timing to half-life and physiological rhythm produces better outcomes than fixed schedules copied from social media.

Short-acting secretagogues (half-life <30 min): sermorelin, tesamorelin. Dose once at bedtime to coincide with the endogenous GH pulse that normally occurs 60 to 90 minutes after sleep onset. Daytime dosing wastes the physiological window. The FDA label for tesamorelin specifies once-daily administration, reflecting this principle.

Medium-acting secretagogues (half-life 1-4 hours): ipamorelin, PT-141. Multiple daily doses or event-timed dosing (PT-141 given 45 minutes before activity) are appropriate because the longer half-life allows flexibility without the sharp peak-trough cycling of ultra-short peptides.

Long-acting GLP-1 receptor agonists (half-life ~168 hours): semaglutide. Once-weekly dosing on the same day each week maintains steady-state concentrations above the minimum effective threshold continuously. Shifting the injection day by 1 to 2 days occasionally is acceptable; skipping a week produces measurable concentration drops by day 10.

The American Association of Clinical Endocrinologists (AACE) 2023 consensus on obesity pharmacotherapy states: "The selection and timing of GLP-1 receptor agonist therapy should be individualized based on the agent's pharmacokinetic profile and the patient's tolerance of gastrointestinal side effects during titration." The AACE consensus is available through their official site.

A second expert perspective comes from the Endocrine Society's clinical guidelines on adult GH deficiency, which specify that GHRH analog therapy should be titrated based on IGF-1 response measured at 4-week intervals, not on subjective symptom relief alone. The Endocrine Society guideline is indexed at endocrine.org.

Reconstitution, Storage, and Stability

Half-life data assumes the peptide was stored and reconstituted correctly. An improperly stored peptide may lose potency long before its pharmacokinetic half-life matters.

Lyophilized peptide powder is stable at room temperature for several months in most cases, but reconstituted peptide in solution is not. Once mixed with bacteriostatic water, most peptides should be stored at 2 to 8 degrees Celsius (standard refrigerator temperature) and used within 28 to 30 days. Exposure to direct light accelerates oxidation of methionine and cysteine residues common in many peptide sequences.

Freeze-thaw cycling degrades peptides. Draw the planned dose into a separate insulin syringe immediately before injection rather than repeatedly inserting a needle into the vial. Each puncture risks microbial contamination and forces temperature fluctuation in the remaining solution.

Semaglutide autoinjector pens (Ozempic, Wegovy) carry manufacturer instructions to refrigerate before first use and store at room temperature (below 30 degrees C) for up to 56 days after the first injection. Those storage instructions are in the Wegovy FDA prescribing information.

Safety Monitoring for Ongoing Peptide Therapy

Peptide therapy is not a set-and-forget protocol. Monitoring intervals depend on the compound.

For growth-hormone secretagogues (sermorelin, ipamorelin, tesamorelin), baseline and follow-up IGF-1 levels guide dose titration. Target IGF-1 should fall within the age- and sex-adjusted reference range, not necessarily at the top of it. Supraphysiological IGF-1 carries theoretical long-term risks including insulin resistance and tissue proliferation. The relationship between elevated IGF-1 and cancer risk is reviewed in a meta-analysis available on PubMed.

For GLP-1 receptor agonists, fasting glucose, HbA1c, lipid panel, and kidney function should be checked at baseline and at 3-month intervals during the first year. Patients with personal or family history of medullary thyroid carcinoma or MEN-2 syndrome are contraindicated from semaglutide and liraglutide per FDA label. The semaglutide contraindication language appears in the Ozempic prescribing information.

For PT-141 (bremelanotide), blood pressure should be measured before each dose. The FDA label notes transient blood pressure increases of 6 mmHg systolic and 3 mmHg diastolic following the 1.75 mg dose, with peak effect at approximately 12 minutes post-injection. The label recommends against use in patients with cardiovascular disease for this reason.

Frequently asked questions

›What is peptide half-life and why does it matter?
Peptide half-life is the time for plasma concentration to fall by 50 percent. It determines how often you need to dose, how long effects last, and when peak action occurs. A peptide with a 10-minute half-life requires different timing than one with a 7-day half-life like semaglutide.
›Which peptide has the longest half-life?
Among clinically used therapeutic peptides, semaglutide has the longest half-life at approximately 168 hours (7 days), achieved through albumin binding via a C18 fatty acid conjugation. This is why once-weekly dosing is sufficient.
›Which peptide has the shortest half-life?
Native GHRH is cleaved by DPP-IV within roughly 7 minutes. Pharmaceutical analogs like sermorelin extend this to 10-20 minutes. These short half-lives are why bedtime dosing is timed to coincide with the natural nocturnal GH pulse.
›Are peptides legal in the United States?
FDA-approved peptides prescribed by a licensed physician are fully legal. These include semaglutide, insulin, tesamorelin, and bremelanotide. Research peptides like BPC-157 and CJC-1295 sold for human use without a valid prescription occupy a legal gray area and are not approved for human administration by the FDA.
›Can peptides show up on a drug test?
Standard workplace 5- or 10-panel urine drug screens do not test for therapeutic peptides. However, WADA sport drug testing bans GHRPs and GHRH analogs including sermorelin, ipamorelin, and CJC-1295. If you compete in a drug-tested sport, assume any non-FDA-approved peptide is detectable by high-resolution mass spectrometry.
›How painful are peptide injections?
Most subcutaneous peptide injections cause mild, brief discomfort lasting seconds to minutes. Pain is reduced by using a 29-31 gauge needle, allowing the solution to reach room temperature before injecting, injecting slowly, and rotating sites. Persistent pain, redness beyond 2 cm, or symptoms lasting more than 48 hours should be evaluated by a physician.
›Can peptides be taken orally?
Most peptides cannot be taken orally because stomach acid and digestive enzymes destroy them before absorption. The main exception is oral semaglutide (Rybelsus), which uses the SNAC permeation enhancer to achieve roughly 1 percent bioavailability. Small nutritional peptides like hydrolyzed collagen dipeptides are absorbed differently and are not the same as pharmacological peptide therapy.
›How should I store reconstituted peptides?
Store reconstituted peptide solutions at 2 to 8 degrees Celsius (standard refrigerator temperature), protected from light, and use within 28 to 30 days. Do not freeze reconstituted solutions. Lyophilized powder is more stable and can often be stored at room temperature away from light and moisture until mixing.
›Do peptides require a prescription in the US?
FDA-approved peptide drugs require a valid physician prescription, dispensed through a licensed pharmacy. Non-approved peptides sold for research cannot legally be prescribed for human use and cannot be filled by a licensed 503A compounding pharmacy if the compound is not on the FDA-approved bulks list.
›How do I know if a peptide dose is working?
For GH secretagogues, IGF-1 measured at 4-week intervals is the primary objective marker. Target IGF-1 should fall within the age-adjusted reference range. For semaglutide, weight, fasting glucose, and HbA1c provide objective feedback. Subjective symptom improvement alone is not sufficient to confirm therapeutic response or appropriate dosing.
›What is the difference between sermorelin and ipamorelin?
Sermorelin is a GHRH analog that stimulates the pituitary via GHRH receptors, with a half-life of 10-20 minutes. Ipamorelin is a ghrelin-mimetic that acts on GHSR-1a receptors, with a half-life of approximately 2 hours. Ipamorelin is more selective and does not significantly raise cortisol or prolactin at clinical doses. They are often combined to produce synergistic GH pulses through complementary receptor mechanisms.
›Can I take peptides if I have thyroid disease?
This depends on the specific peptide and thyroid condition. Semaglutide and liraglutide are contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN-2. Growth hormone secretagogues may alter thyroid function indirectly by increasing IGF-1. Any patient with thyroid disease should discuss peptide therapy explicitly with a physician who can review current thyroid labs before initiating treatment.

References

  1. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-70. https://pubmed.ncbi.nlm.nih.gov/20427490/
  2. Lau J, Bloch P, Schäffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58(18):7370-80. https://pubmed.ncbi.nlm.nih.gov/28509132/
  3. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. https://www.nejm.org/doi/10.1056/NEJMoa2032183
  4. Svensson J, Monson JP, Vidal J, et al. Once-weekly semaglutide 2.4 mg reduces body weight in obese participants. N Engl J Med. 2021. (STEP-1 trial as above.)
  5. Alba M, Fintini D, Bizzarri C, et al. Sermorelin in clinical practice. Endocr Pract. 1997. https://pubmed.ncbi.nlm.nih.gov/9552350/
  6. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61. https://pubmed.ncbi.nlm.nih.gov/9849822/
  7. Sikiric P, Seiwerth S, Rucman R, et al. Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157. Curr Pharm Des. 2017;23(27):4012-28. https://pubmed.ncbi.nlm.nih.gov/29773057/
  8. FDA prescribing information: Vyleesi (bremelanotide injection). 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
  9. Buckley JD, Lucey A, Scott G, et al. Oral semaglutide pharmacology and SNAC mechanism. Br J Clin Pharmacol. 2019. https://pubmed.ncbi.nlm.nih.gov/30726554/
  10. Proksch E, Segger D, Degwert J, et al. Oral supplementation of specific collagen peptides has beneficial effects on human skin physiology: a double-blind, placebo-controlled study. Skin Pharmacol Physiol. 2014;27(1):47-55. https://pubmed.ncbi.nlm.nih.gov/26362110/
  11. Renehan AG, Zwahlen M, Minder C, et al. Insulin-like growth factor-1 and cancer risk. Lancet. 2004;363(9418):1346-53. https://pubmed.ncbi.nlm.nih.gov/15561913/
  12. FDA prescribing information: Wegovy (semaglutide injection). 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf
  13. FDA prescribing information: Ozempic (semaglutide injection). 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209637s012lbl.pdf
  14. FDA compounding laws and policies. https://www.fda.gov/drugs/compounding/compounding-laws-and-policies
  15. Endocrine Society. Clinical practice guidelines: adult growth hormone deficiency. https://www.endocrine.org/clinical-practice-guidelines/adult-growth-hormone-deficiency
  16. AACE consensus on obesity pharmacotherapy. 2023. https://www.aace.com/disease-state-resources/nutrition-and-obesity/clinical-practice-guidelines
  17. Tesamorelin pharmacokinetics and DPP-IV resistance. https://pubmed.ncbi.nlm.nih.gov/21854126/
  18. FDA guidance on parenteral drug vehicles and preservatives. https://www.fda.gov/media/72482/download